Role of the transcription factor NF-κB in the cardiac cell;El papel del factor de transcripción NF-κB en la célula cardíaca

Archivos de Cardiologia de Mexico

Volumn 75, Issue 3, 2005, Pages 363-370

  Hernández Gutiérrez, Salomón ^a,b   Rojas Del Castillo, Emilio ^b  

^a UNIVERSIDAD PANAMERICANA   (Mexico)

^b INSTITUTO DE INVESTIGACIONES BIOMÉDICAS   (Mexico)

Author keywords

Apoptosis; Cardiomyocytes; Nuclear factor B (NF B)

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR AP 1;

APOPTOSIS; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CELL DEATH; HEART ARREST; HEART INFARCTION; HEART MUSCLE CELL; HEART MUSCLE ISCHEMIA; HEART MUSCLE REPERFUSION; HUMAN; ISCHEMIC HEART DISEASE; REPERFUSION INJURY; REVIEW;

ANIMALS; APOPTOSIS; CARDIOMEGALY; CELLS, CULTURED; CORONARY ARTERIOSCLEROSIS; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; HEART ARREST; HOMEOSTASIS; HUMANS; ISCHEMIC PRECONDITIONING, MYOCARDIAL; MYOCARDIAL INFARCTION; MYOCARDIAL ISCHEMIA; MYOCARDIAL REPERFUSION INJURY; MYOCYTES, CARDIAC; NF-KAPPA B; OXIDATIVE STRESS; PHENOTYPE; RABBITS; RATS; TIME FACTORS;

EID: 27644473727     PISSN: 14059940     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (36)

1. VALEN G, YAN Z, HANSSON G: Nuclear Factor Kappa-B and the Heart. J Am Coll Cardiol 2001; 38(2): 307-314.
2. SEN R, BALTIMORE D: Inducibility of kappa immunoglobulin enhancer-binding protein Nf-kappa B by a posttranslational mechanism. Cell 1986; 47(6): 921-928.
3. BALDWIN AS: The NF-κB and IkB proteins: new discoveries and insights. Annu Rev Immunol 1996; 14: 649-681.
4. MIYAMOTO S, VERMA IM: Rel/NF-kappa B/I kappa B story. Adv Cancer Res 1995; 66: 255-292.
5. BALLARD DW, DIXON EP, PEFFER NJ, BOGERD H, DOERRE S, STEIN B, ET AL: The 65-kDa subunit of human NF-kappa B functions as a potent transcriptional activator and a target for v-Rel-mediated repression. PNAS 1992; 89(5): 1875-1879.
6. CHEN F, CASTRANOVA V, SHI X, DEMERS LM: New insights into the role of nuclear factor-kappaB, a ubiquitous transcription factor in the initiation of diseases. Clin Chem 1999; 45(1): 7-17.
7. GHOSH S, MAY MJ, KOPP EB: NF-kappa B and Rel proteins: evolutionary conserved mediators of immune responses. Annu Rev Immunol 1998; 16: 225-260.
8. BAEUERLE PA, HENKEL T: Function and activation of NF-kappa B in the immune system. Annu Rev Immunol 1994; 12: 141-179.
9. BOURS V, BONIZZI G, BENTIRES-ALJ M, BUREAU F, PIETTE J, LEKEUX P, ET AL: NF-kappaB activation in response to toxical and therapeutical agents: role in inflammation and cancer treatment. Toxicol 2000; 153(1-3): 27-38.
10. BARNES PJ, ADCOCK IM: NF-kappa B: a pivotal role in asthma and a new target for therapy. Trends Pharmacol Sci 1997; 18(2): 46-50.
11. THURBERG BL, COLLINS T: The nuclear factor-kappa B/inhibitor of kappa B autoregulatory system and atherosclerosis. Curr Opin Lipidol 1998; 9(5): 387-396.
12. CRAIG R, WAGNER M, MCCARDLE T, CRAIG AG, GLEMBOTSKI CC: The cytoprotective effects of the glycoprotein 130 receptor-coupled cytokine, cardiotrophin-1, require activation of NF-kappa B. J Biol Chem 2001; 276(40): 37621-37629.
13. MUSTAPHA S, KIRSHNER A, DE MOISSAC D, KIRSHENBAUM L: A direct requirement of nuclear factor κB for suppression of apoptosis in ventricular myocytes. Am J Physiol Heart Circ Physiol 2000; 279: H939-H945.
14. BERGMANN MW, LOSER P, DIETZ R, HARSDORF R: Effect of NF-κB inhibition on TNFα induced apoptosis and downstream pathway in cardiomyocytes. J Mol Cell Cardiol 2001; 33: 1223-1232.
15. DE MOISSAC D, SHENG H, KIRSHEMBAUM L. A: Linkage of the BH4 domain of Bcl-2 and the Nuclear Factor κB signaling pathway suppression of apoptosis. J Biol Chem 1999; 274 (41): 29505-29509.
16. PURCELL N, TANG G, YU C, MERCURIO F, DIDONATO J, LIN A: Activation of NF-κB is required for hypertrophic growth of primary rat neonatal ventricular cardiomyocytes. PNAS 2001; 98(12): 6668-6673.
17. HIGUCHI Y, OTSU K, NISHIDA K, HIROTANI S, NAKAYAMA H, YAMAGUCHI O, ET AL: Involvement of reactive oxygen species-mediated NF-kappa B activation in TNF-alpha-induced cardiomyocyte hypertrophy. J Mol Cell Cardiol 2002; 34(2): 233-240.
18. LI C, BROWDER W, KAO RL: Early activation of transcription factor NF-κB during ischemia in perfused rat heart. Am J Physiol 1999; 276: H543-H552.
19. CHANDRASEKAR B, FREEMAN GL: Induction of nuclear factor kB and activation protein-1 in postischemic myocardium. FEBS Lett 1997; 401: 30-34.
20. SHIMIZU N, YOSHIYAMA M, OMURA T, HANATANI A, KIM S, TAKEUCHI K: Activation of mitogen activated protein kinases and activator protein-1 in myocardial infarction in rats. Cardiovasc Res 1998; 38: 116-124.
21. SUN B, FAN H, HONDA T, FUJIMAKI R, LAFOND-WALKER A, MASUI Y, ET AL: Activation of NF kappa B and expression of ICAM-1 in ischemic-reperfused canine myocardium. J Mol Cell Cardiol 2001; 33(1): 109-119.
22. MORGAN E, BOYLE E, YUN W, GRISCAVAGE-ENNIS J, FARR AL, CANTY T, ET AL: An essential role for NF-kappaB in the cardioadaptive response to ischemia. Ann Thorac Surg 1999; 68(2): 377-382.
23. PYE J, ARDESHIRPOUR F, MCCAIN A, BELLINGER DA, MERRICKS E, ADAMS J, ET AL: Proteasome inhibition ablates activation of NF-kappa B in myocardial reperfusion and reduces reperfusion injury. Am J Physiol Heart Circ Physiol 2002; 284(3): H919-H926.
24. YAMASAKI K, ASAI T, SHIMIZU M, AOKI M, HASHIYA N, SAKONJO H, ET AL: Inhibition of NFkappaB activation using cis-element decoy of NFkappaB binding site reduces neointimal formation in porcine balloon-injured coronary artery model. Gene Ther 2003; 10(4): 356-364.
25. FEELEY BT, MINIATI D, PARK AK, HOYT EG, ROBINS RC: Nuclear factor-KappaB transcription factor decoy treatment inhibits graft coronary artery disease after cardiac transplantation in rodents. Transplant 2000; 15: 70(11): 1560-1568.
26. MAULIK N, SATO M, PRICE BD, DAS DK: An essential role of NFkappaB in tyrosine kinase signaling of p38 MAP kinase regulation of myocardial adaptation to ischemia. FEBS Lett 1998; 16: 429(3): 365-369.
27. MELDRUM DR: Mechanisms of cardiac preconditioning: ten years after the discovery of ischemic preconditioning. J Surg Res 1997; 73(1): 1-13.
28. TAHEPOLD P, VAAGE J, STARKOPF J, VALEN G: Hyperoxia elicits myocardial protection through a nuclear factor kappaB-dependent mechanism in the rat heart. J Thorac Cardiovasc Surg 2003; 125(3): 650-660.
29. MORGAN HE, GORDON E, KIRA E, CHUA B, RUSSO L, PETERSON CJ, ET AL: Biochemical mechanisms of cardiac hypertrophy. Annu Rev Physiol 1987; 49: 533-543.
30. CHIEN KR, KNOWLTON KU, ZHU H, CHIEN S: Regulation of cardiac gene expression during myocardial growth and hypertrophy: molecular studies of an adaptive physiologic response. FASEB J 1991; 5: 3037-3046.
31. BRAND K, PAGE S, ROGIER G, BARTSH A, BRAND R, KNUECHEL R: Actived transcription factor nuclear factor-kappa B is present in the atherosclerotic lesion. J Clin Invest 1996; 97(7): 1715-1722.
32. COLLINS T, CYBULSKY MI: NF-kappaB: pivotal mediator or innocent bystander in atherogenesis? J Clin Invest 2001; 107(3): 255-264.
33. ROSS R: The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 1993; 362: 801-808.
34. BRAND K, PAGE S, WALLI AK, NEUMEIER D, BAEUERLE PA: Role of nuclear factor-kappa B in atherogenesis. Exp Physiol 1997; 82(2): 297-304.
35. FRANTZ S, FRACCAROLLO D, WAGNER H, BEHR TM, JUNG P, ANGERMANN CE, ET AL: Sustained activation of nuclear factor kappa B and activator protein 1 in chronic heart failure. Cardiovasc Res 2003; 57(3): 749-756.
36. STEENBERGEN C, AFSHARI C, PETRANKA J, COLLINS J, MARTIN K, BENNETT L, ET AL: Alteration in apoptotic signalling in human idiopathic cardiomyopathic hearts in failure. Am J Phisiol Heart Circ Physiol 2003; 284: H266-H276.